Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-203a-3p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0040H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Serum, Whole blood, Tissue

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.26 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 8.7%

Inter-assay (Run-to-Run)

n = 5,
CV = 8.1%

Spiking Recovery

103.0%

Dilution Linearity

102.3%

Specificity

Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.

Note

Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.


Product Manual: miREIA - microRNA enzyme immunoassay

 

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-203a-3p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Oncology

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-203a has been found to be a crucial regulator involved in various malignancies, such as gastric cancer (GC), nasopharyngeal carcinoma (NPC), breast cancer, lung cancer, liver cancer, and colorectal cancer (CRC). The expression of miR-203a-3p was decreased in NPC tissues and cell lines in comparison with normal nasopharyngeal tissues and cell line. miR-203a-3p suppresses tumor growth and metastasis through targeting LASP1 in NPC. miR-203a-3p was also down-regulated in non-small cell lung cancer (NSCLC) tissues and cells compared with normal tissues and cells. miR-203a-3p together with other three miRNAs (miR-7-5p, miR-145-5p and miR-192-5p) were reported to be down-regulated in hepatocellular carcinoma (HCC), and could inhibit HCC progression by modulating expression of multiple target genes. Decrease of TFF3 was associated with increase of miR-203a-3p in plasma of HCC patients and these molecules displayed potent predictive power for HCC diagnosis. It was published that IGF-1R is a direct co-target of miR-99b-5p/203a-3p that may function as tumor suppressive miRNAs by negatively regulating IGF-1R expression in GC cells. In another study, significant downregulation and proximal promoter methylation of miR-203a and miR-203b in gastric cardia adenocarcinoma (GCA) tissues was found. The methylation status of miR-203a and miR-203b in tumor tissues was negatively correlated with their expression level. GCA patients in stage III and IV with reduced expression or hypermethylation of miR-203a demonstrated poor survival. In conclusion, miR-203a and miR-203b may function as tumor suppressive miRNAs, and reactivation of miR-203a may have therapeutic potential GCA patients. miR-203a-3p also promotes colorectal cancer cell proliferation, colony formation and migration and invasion which suggests that miR-203a-3p may be a novel molecular therapeutic target for CRC.

Up-regulation of miR-203a-3p might inhibit pathological retinal angiogenesis in proliferative diabetic retinopathy (PDR). Expression levels of miR-335-5p, miR-485-5p, miR-16-5p, miR-150-5p, miR-34a-5p, and miR-203a-3p were significantly increased in PBMCs from patients with rheumatoid arthritis (RA) compared with healthy controls.

Summary References (14)

References to miR-203a-3p

  • Ebrahimiyan H, Rezaei N, Vojdanian M, Aslani S, Jamshidi A, Mahmoudi M.microRNA involvement in the regulation of survivin in peripheral bloodmononuclear cells from rheumatoid arthritis patients. Int J Rheum Dis. 2019Jun;22(6):1107-1114. doi: 10.1111/1756-185X.13520. Epub 2019 Mar 5. PubMed PMID: 30834699. See more on PubMed
  • Gomes BC, Martins M, Lopes P, Morujão I, Oliveira M, Araújo A, Rueff J,Rodrigues AS. Prognostic value of microRNA-203a expression in breast cancer.Oncol Rep. 2016 Sep;36(3):1748-56. doi: 10.3892/or.2016.4913. Epub 2016 Jul 5.PubMed PMID: 27431784. See more on PubMed
  • Han N, Xu H, Yu N, Wu Y, Yu L. MiR-203a-3p inhibits retinal angiogenesis andalleviates proliferative diabetic retinopathy in oxygen-induced retinopathy (OIR)rat model via targeting VEGFA and HIF-1α. Clin Exp Pharmacol Physiol. 2020Jan;47(1):85-94. doi: 10.1111/1440-1681.13163. Epub 2019 Oct 7. PubMed PMID:31408201. See more on PubMed
  • Chen L, Gao H, Liang J, Qiao J, Duan J, Shi H, Zhen T, Li H, Zhang F, Zhu Z,Han A. miR-203a-3p promotes colorectal cancer proliferation and migration bytargeting PDE4D. Am J Cancer Res. 2018 Dec 1;8(12):2387-2401. eCollection 2018.PubMed PMID: 30662799; PubMed Central PMCID: PMC6325478. See more on PubMed
  • Chen QF, Kong JL, Zou SC, Gao H, Wang F, Qin SM, Wang W. LncRNA LINC00342regulated cell growth and metastasis in non-small cell lung cancer via targeting miR-203a-3p. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7408-7418. doi:10.26355/eurrev_201909_18849. PubMed PMID: 31539128. See more on PubMed
  • Jiang N, Jiang X, Chen Z, Song X, Wu L, Zong D, Song D, Yin L, Wang D, Chen C,Bian X, He X. MiR-203a-3p suppresses cell proliferation and metastasis throughinhibiting LASP1 in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2017 Oct5;36(1):138. doi: 10.1186/s13046-017-0604-3. PubMed PMID: 28982387; PubMedCentral PMCID: PMC5629759. See more on PubMed
  • Lewis DD, Vajentic AK, Nelson KA. Thirty hours from referral to cross-clamp: acase study in organ procurement. J Transpl Coord. 1996 Jun;6(2):75-7. PubMedPMID: 9188362. See more on PubMed
  • Lin QH, Zhang KD, Duan HX, Liu MX, Wei WL, Cao Y. ERGIC3, which is regulatedby miR-203a, is a potential biomarker for non-small cell lung cancer. Cancer Sci.2015 Oct;106(10):1463-73. doi: 10.1111/cas.12741. Epub 2015 Aug 10. PubMed PMID: 26177443; PubMed Central PMCID: PMC4638005. See more on PubMed
  • Liu W, Dong Z, Liang J, Guo X, Guo Y, Shen S, Kuang G, Guo W. Downregulationof Potential Tumor Suppressor miR-203a by Promoter Methylation Contributes to theInvasiveness of Gastric Cardia Adenocarcinoma. Cancer Invest. 2016 Nov25;34(10):506-516. Epub 2016 Oct 28. PubMed PMID: 27791400. See more on PubMed
  • Qiu L, Wang T, Ge Q, Xu H, Wu Y, Tang Q, Chen K. Circular RNA Signature inHepatocellular Carcinoma. J Cancer. 2019 Jun 9;10(15):3361-3372. doi:10.7150/jca.31243. eCollection 2019. PubMed PMID: 31293639; PubMed Central PMCID:PMC6603403. See more on PubMed
  • Wang Z, Zhao Z, Yang Y, Luo M, Zhang M, Wang X, Liu L, Hou N, Guo Q, Song T,Guo B, Huang C. MiR-99b-5p and miR-203a-3p Function as Tumor Suppressors byTargeting IGF-1R in Gastric Cancer. Sci Rep. 2018 Jul 4;8(1):10119. doi:10.1038/s41598-018-27583-y. PubMed PMID: 29973668; PubMed Central PMCID:PMC6031697. See more on PubMed
  • Yang H, Wang L, Tang X, Bai W. miR-203a suppresses cell proliferation bytargeting E2F transcription factor 3 in human gastric cancer. Oncol Lett. 2017Dec;14(6):7687-7690. doi: 10.3892/ol.2017.7199. Epub 2017 Oct 17. PubMed PMID:29344215; PubMed Central PMCID: PMC5755138. See more on PubMed
  • Zhang C, Xia R, Zhang B, Wang H. The predictive powers of plasma trefoilfactor 3 or its related micro RNAs for patients with hepatocellular carcinoma.BMC Cancer. 2018 Nov 13;18(1):1110. doi: 10.1186/s12885-018-5017-y. PubMed PMID: 30424721; PubMed Central PMCID: PMC6234585. See more on PubMed
  • Zhang L, He X, Jin T, Gang L, Jin Z. Long non-coding RNA DLX6-AS1 aggravateshepatocellular carcinoma carcinogenesis by modulating miR-203a/MMP-2 pathway.Biomed Pharmacother. 2017 Dec;96:884-891. doi: 10.1016/j.biopha.2017.10.056. Epub2017 Nov 6. PubMed PMID: 29145165. See more on PubMed
Related Products Docs